Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Company Overview - Soleno Therapeutics, Inc. (NASDAQ: SLNO) specializes in rare diseases, particularly focusing on Prader-Willi Syndrome (PWS) hyperphagia, a condition characterized by insatiable hunger that significantly impacts patients' quality of life [1]. Drug Candidate - The company’s leading drug candidate, DCCR, has shown effectiveness in reducing hunger associated with PWS, addressing a critical unmet medical need as there are currently no approved treatments for this condition [1].